Grufity logoGrufity logo

Arcus Biosciences Inc Stock Research

RCUS

23.13USD+0.04(+0.17%)Market Closed

Market Summary

USD23.13+0.04
Market Closed
0.17%

RCUS Stock Price

RCUS RSI Chart

RCUS Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

20.97

Price/Sales (Trailing)

3.87

EV/EBITDA

16.46

Price/Free Cashflow

3.88

RCUS Price/Sales (Trailing)

RCUS Profitability

EBT Margin

19.09%

Return on Equity

11.42%

Return on Assets

5.73%

Free Cashflow Yield

25.78%

RCUS Fundamentals

RCUS Revenue

Revenue (TTM)

432.8M

Revenue Y/Y

254.94%

Revenue Q/Q

25.49%

RCUS Earnings

Earnings (TTM)

79.8M

Earnings Y/Y

16.74%

Earnings Q/Q

2.57%

Price Action

52 Week Range

16.7439.75
(Low)(High)

Last 7 days

8.8%

Last 30 days

17.4%

Last 90 days

-16.7%

Trailing 12 Months

-21%

RCUS Financial Health

Current Ratio

6.21

RCUS Investor Care

Shares Dilution (1Y)

3.20%

Peers (Alternatives to Arcus Biosciences)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
135.3B
26.3B
-2.97% 16.81%
19.8
5.14
2.18% 21.86%
105.0B
27.1B
-0.99% 30.15%
31.49
3.87
-1.26% -54.91%
73.3B
21.4B
7.28% 27.41%
6.23
3.43
80.80% 66.62%
41.9B
10.4B
5.85% 32.49%
14.62
4.04
-6.64% 85.32%
10.4B
1.4B
-8.79% 49.41%
178.74
7.49
29.86% -86.92%
MID-CAP
3.9B
-
18.31% 0.06%
-12.88
32.03
-41.50% -1123.42%
3.2B
-
23.33% -24.11%
-10.12
59.51
215916.67% 21.41%
SMALL-CAP
1.7B
432.8M
17.41% -21.00%
20.97
3.87
1042.97% 128.67%
1.4B
-
35.16% 1.79%
-2.74
20.84
745.14% 12.80%
1.3B
3.1M
-3.43% 39.57%
-8.78
417.83
7.05% -46.74%
886.0M
1.8B
24.61% -84.52%
-0.67
0.48
53.41% -22.97%
574.9M
69.0M
-39.96% -83.45%
-1.96
8.33
26.22% -49.52%
565.8M
112.1M
28.78% -35.14%
-3.18
5.05
3.26% 1.99%
142.4M
-
42.67% -74.19%
-1.36
418.24
-71.03% -64.56%
6.7M
-
67.66% -93.12%
-0.11
3.21
0.51% -141.69%

Financials for Arcus Biosciences

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue5.9%43340939138338
Operating Expenses4.5%357342332329317
  S&GA Expenses11.1%9989807262
  R&D Expenses2.2%258252251256255
EBITDA18.3%8875-281.4258-
EBITDA Margin11.7%0.20*0.18*-0.72*0.15*-
Earnings Before Taxes18.8%83706055-302.05
EBT Margin12.1%0.19*0.17*-0.73*0.14*-
Net Income19.6%80675753-278.39
Net Income Margin12.9%0.18*0.16*0.15*0.14*-
Free Cahsflow-4.6%432452439-282.25-
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-5.6%1,3941,4771,5431,592839
  Current Assets-10.3%1,1011,2271,2641,262545
    Cash Equivalents-20.2%218273549148179
  Net PPE1.4%3433333229
Liabilities-4.7%695729747750297
  Current Liabilities8.0%177164161166143
Shareholder's Equity-6.5%699747797841543
  Retained Earnings-15.8%-474.90-409.98-343.35-275.35-554.72
  Additional Paid-In Capital1.6%1,1831,1651,1451,1181,097
Accumulated Depreciation-18----
Shares Outstanding0.4%7272727170
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-5.8%446473464-256.17-243.95
  Share Based Compensation2.8%6261585549
Cashflow From Investing20.3%-440.90-552.95-334.75-3.87-23.01
Cashflow From Financing3.8%333230237227

Risks for RCUS

What is the probability of a big loss on RCUS?

94.2%


Probability that Arcus Biosciences stock will be more than 20% underwater in next one year

94.2%


Probability that Arcus Biosciences stock will be more than 30% underwater in next one year.

82.5%


Probability that Arcus Biosciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RCUS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.

Drawdowns

Returns for RCUS

Cumulative Returns on RCUS

33.7%


3-Year Cumulative Returns

Which funds bought or sold RCUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-26
OREGON PUBLIC EMPLOYEES RETIREMENT FUND
added
0.45
-93,429
358,571
-%
2023-01-26
State of Tennessee, Treasury Department
added
6.82
82,000
872,000
-%
2023-01-26
COMERICA BANK
reduced
-21.87
-474,000
630,000
-%
2023-01-26
STRS OHIO
reduced
-19.94
-313,000
539,000
-%
2023-01-26
Inspire Investing, LLC
added
44.81
30,186
236,186
0.03%
2023-01-25
Versant Capital Management, Inc
reduced
-16.67
207
207
-%
2023-01-25
FIFTH THIRD BANCORP
unchanged
-
-3,248
13,752
-%
2023-01-24
NATIONAL BANK OF CANADA /FI/
unchanged
-
-933
2,067
-%
2023-01-24
Louisiana State Employees Retirement System
unchanged
-
-136,000
513,000
0.01%
2023-01-23
Allspring Global Investments Holdings, LLC
reduced
-6.27
-89,210
255,790
-%

1–10 of 45

Latest Funds Activity

Are funds buying RCUS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RCUS
No. of Funds

Arcus Biosciences News

ETF Daily News

Arcus Biosciences, Inc. (NYSE:RCUS) Holdings Boosted by Oregon ....

ETF Daily News,
44 hours ago

Marketing Sentinel

Investor's Business Daily

Investor's Business Daily

Schedule 13G FIlings of Arcus Biosciences

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 26, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Jan 20, 2023
blackrock inc.
13.0%
9,389,048
SC 13G/A
Oct 17, 2022
pfm health sciences, lp
5.5%
6
SC 13G
May 09, 2022
blackrock inc.
11.1%
7,967,677
SC 13G
Mar 14, 2022
biotechnology value fund l p
3.0%
2,156,510
SC 13G
Feb 14, 2022
gv 2016, l.p.
0.91%
638,967
SC 13G/A
Feb 14, 2022
pfm health sciences, lp
4.9%
6
SC 13G/A
Feb 14, 2022
ecor1 capital, llc
7.9%
5,523,358
SC 13G/A
Feb 04, 2022
blackrock inc.
5.9%
4,129,929
SC 13G
Jul 19, 2021
ecor1 capital, llc
6.4%
4,572,047
SC 13G

RCUS Fair Value

Recent SEC filings of Arcus Biosciences

View All Filings
Date Filed Form Type Document
Jan 26, 2023
SC 13G/A
Major Ownership Report
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 25, 2023
4
Insider Trading
Jan 20, 2023
SC 13G/A
Major Ownership Report
Dec 19, 2022
8-K
Current Report
Dec 16, 2022
4
Insider Trading

Latest Insider Trading transactions for RCUS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-01-23
ROSEN TERRY J
acquired
-
-
105,700
chief executive officer
2023-01-23
Goeltz II Robert C.
acquired
-
-
34,000
chief financial officer
2023-01-23
Jarrett Jennifer
acquired
-
-
45,800
chief operating officer
2023-01-23
Nuyten Dimitry SA
acquired
-
-
34,000
chief medical officer
2023-01-23
Tang Carolyn C.
acquired
-
-
34,000
general counsel
2023-01-23
Jaen Juan C.
acquired
-
-
45,800
president
2022-12-16
ROSEN TERRY J
sold
-401,073
30.75
-13,043
chief executive officer
2022-12-16
Goeltz II Robert C.
sold
-75,429.6
30.7499
-2,453
chief financial officer
2022-12-16
Jarrett Jennifer
sold
-506,822
30.75
-16,482
chief operating officer
2022-12-16
Jaen Juan C.
sold
-136,407
30.7501
-4,436
president

1–10 of 50

Terry J. Rosen
370
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 33,581$ 9,461$ 78,345$ 28,383
Operating expenses:    
Research and development (($26,560), ($756), ($92,667) and ($6,856) from a related party)76,68471,254207,800206,412
General and administrative (($493), $0, ($690) and $0 from a related party)26,29416,34376,10448,990
Total operating expenses102,97887,597283,904255,402
Loss from operations(69,397)(78,136)(205,559)(227,019)
Non-operating income (expense):    
Interest and other income, net5,0131618,456481
Effective interest on liability for sale of future royalties(535) (1,437) 
Total non-operating income, net4,4781617,019481
Net loss before income taxes(64,919)(77,975)(198,540)(226,538)
Income tax expense00(1,004)0
Net loss(64,919)(77,975)(199,544)(226,538)
Other comprehensive loss(2,557)(46)(8,540)(136)
Comprehensive loss$ (67,476)$ (78,021)$ (208,084)$ (226,674)
Net loss per share, basic$ (0.90)$ (1.11)$ (2.78)$ (3.28)
Net loss per share, diluted$ (0.90)$ (1.11)$ (2.78)$ (3.28)
Weighted-average number of shares used to compute basic net loss per share72,236,28370,110,13871,752,24668,990,290
Weighted-average number of shares used to compute diluted net loss per share72,236,28370,110,13871,752,24668,990,290
License and Development Services Revenue    
Revenues:    
Total revenues$ 23,742 $ 48,374 
Other Collaboration Revenue    
Revenues:    
Total revenues$ 9,839$ 9,461$ 29,971$ 28,383

RCUS Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Jun. 30, 2022
Dec. 31, 2021
Current assets:   
Cash and cash equivalents$ 217,647 $ 147,914
Short-term investments831,135 351,394
Receivable from collaboration partners ($26,521 and $744,535 from a related party)27,286 744,595
Accrued interest receivable3,423 2,227
Prepaid expenses and other current assets21,625 15,620
Total current assets1,101,116 1,261,750
Long-term investments143,138 181,990
Property and equipment, net33,892 32,455
Right-of-use assets102,073 104,968
Restricted cash3,005 3,005
Other long-term assets ($1,856 and $0 from a related party)10,598 7,730
Total assets1,393,822 1,591,898
Current liabilities:   
Accounts payable10,546 10,261
Accrued research and development39,827 29,587
Other accrued liabilities20,528 24,181
Deferred revenue, current ($103,291 and $96,981 to a related party)103,291 102,003
Other current liabilities2,984 52
Total current liabilities177,176 166,084
Deferred revenue, noncurrent ($382,584 and $462,217 to a related party)382,584 462,217
Operating lease liabilities, noncurrent119,195 116,887
Other long-term liabilities16,166 5,260
Total liabilities695,121 750,448
Commitments (Note 11) 
Stockholders’ equity:   
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding0 0
Common stock, $0.0001 par value, 400,000,000 shares authorized; 72,352,380 and 70,781,736 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. Shares outstanding includes zero and 9,946 shares issued but subject to vesting as of September 30, 2022 and December 31, 2021, respectively7 7
Additional paid-in capital1,183,393 1,118,058
Accumulated deficit(474,898) (275,354)
Accumulated other comprehensive loss(9,801) (1,261)
Total stockholders’ equity698,701$ 747,386841,450
Total liabilities and stockholders’ equity$ 1,393,822 $ 1,591,898